This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read BioVie’s 8K filing here.
About BioVie
BioVie Inc, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of chronic debilitating conditions in the United States. Its products pipeline includes BIV201, which completed Phase IIa clinical trial for the treatment of ascites caused due to chronic liver cirrhosis; and NE3107, a potentially selective inhibitor of inflammatory extracellular single-regulated kinase, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease, as well as Phase 2 clinical trial for the treatment of Parkinson's disease.
Recommended Stories
- Five stocks we like better than BioVie
- Canada Bond Market Holiday: How to Invest and Trade
- Why Meta’s Pre-Earnings Dip Could Be A Golden Entry Opportunity
- What Do S&P 500 Stocks Tell Investors About the Market?
- Spirit Airlines Stock Nearly Doubled: Are Clear Skies Ahead?
- Why Invest in 5G? How to Invest in 5G Stocks
- Tesla Stock: Buy the Dips, Sell the Rips